C. difficile is a bacterium that is common in the environment. According to the Center for Disease Control and Prevention, approximately 337,000 cases of CDI are reported each… read more.
Website may help curb healthcare costs, kids affected by chronic condition
by Thomas R. Collins – Using everolimus for immunosuppression in heart transplant recipients, along with a reduced amount of cyclosporine, produces results comparable to mycophenolate mofetil,
by Zara Qadir – Five years of evolution in Hospital Pharmacy. The 40th EAHP meeting provided an opportunity for Tajda Miharija-Gala and Juraj Sykora, Directors of Professional Development,… read more.
by Bruce Sylvester – Results from an expanded Phase IB trial presented at ASCO suggest that combination therapy with two investigational and targeted drugs, BRAF inhibitor dabrafenib and… read more.
by Thomas R. Collins – A recently unveiled scoring system for evaluating the likelihood of post-liver transplant survival is useful in predicting success in transplants from donors with… read more.
by Bruce Sylvester – Two studies presented at EASL suggest the real human and economic costs of liver disease across Europe.
C. difficile is a bacterium that is common in the environment. According to the Center for Disease Control and Prevention, approximately 337,000 cases of CDI are reported each… read more.
by Bruce Sylvester – Researchers report that, in the last quarter of the 20th century, changes in smoking behaviors have led to a significant drop in lung cancer… read more.
Emerging uses of EMA Approved Drugs – by Gary Finnegan – The European Medicines Agency is emerging from a turbulent spell which has seen the departure of one… read more.
Emerging uses of FDA Approved Drugs – by Bruce Sylvester – Researchers from a phase 2 study published on March 27 in The Lancet Oncology report that ipilimumab,… read more.
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
